Iams Wealth Management LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 39.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,772 shares of the company’s stock after acquiring an additional 6,769 shares during the quarter. Iams Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,045,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Xponance Inc. lifted its holdings in shares of Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock valued at $380,000 after purchasing an additional 576 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after purchasing an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Novo Nordisk A/S by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after purchasing an additional 2,817 shares during the last quarter. Sunbelt Securities Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.3% during the 2nd quarter. Sunbelt Securities Inc. now owns 10,752 shares of the company’s stock valued at $1,535,000 after purchasing an additional 138 shares during the last quarter. Finally, EP Wealth Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 37.6% during the 2nd quarter. EP Wealth Advisors LLC now owns 65,844 shares of the company’s stock valued at $9,399,000 after purchasing an additional 17,982 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.
Novo Nordisk A/S Stock Performance
NYSE NVO opened at $85.51 on Wednesday. The stock has a 50-day simple moving average of $94.75 and a two-hundred day simple moving average of $114.02. The firm has a market capitalization of $383.73 billion, a P/E ratio of 27.70, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on NVO
Novo Nordisk A/S Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
- Five stocks we like better than Novo Nordisk A/S
- What is the S&P/TSX Index?
- 3 Steel Stocks Soaring After Tariff Announcements
- Best Aerospace Stocks Investing
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Stock Dividend Cuts Happen Are You Ready?
- Why Salesforce Stock Could Be at Fresh Highs by February
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.